OncologyTube Professional - Patients Click Here
12,444 video views
Cancer-News: Videos
01:39
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, explains how Drugs for Long-Term is a New Area for Ovarian Cancer Dont give up on path inhibitors too early because of toxicity.
by:Cancer-News | 13 views
03:53
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Two Trials looking at Inhibitors in 1st-line Therapy Combinations, Cediranib & Olapanib, and Bevacizumab & Olapanib.
by:Cancer-News | 10 views
02:48
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Rucaparib is licensed as a single-agent in the US Patients using Olaparib, benefited for a long period of time.
by:Cancer-News | 15 views
03:01
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Rucaparib, Niraparib, and Olaparib all Show Benefit. Differences between the drugs, are in their toxicities.
by:Cancer-News | 25 views
02:55
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Patients Should Still Test for BRCA Mutations They are in increased risk of breast cancer.
by:Cancer-News | 11 views
02:14
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how ARIEL3 Was a Phase 3 Trial Looking at Rucaparib Significant improvement in progression-fre​e survival.
by:Cancer-News | 16 views
00:53
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers if there is Any association between PDL-1 expression by the tumor?
by:Cancer-News | 11 views
01:51
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains how Gliomas in Mid-Line Locations are Distinct in Both Genetic Makeup and Behavior. Clinical Trial: ONC201 in Adults With Recurrent H3 K27M High-grade Glioma.
by:Cancer-News | 35 views
01:01
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers how Data will not affect clinicians at the moment. Still a Phase 1 study
by:Cancer-News | 9 views
00:50
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers What happens to patients when treatment is stopped?
by:Cancer-News | 9 views
dsfsd